BRUSSELS (Reuters) – Pfizer’s $43 billion bid for Seagen will be decided by EU antitrust regulators by Oct. 19, a regulatory filing showed on Friday.
U.S. pharmaceutical company Pfizer announced the deal, its biggest, in March for Washington-based Seagen, a pioneer of antibody-drug conjugates, which work like “guided missiles” designed to destroy cancer while sparing healthy cells.
The European Commission can either clear the deal after a preliminary review or it can start a four-month long investigation if it has serious concerns.
Pfizer sought EU antitrust approval on Thursday.
(Reporting by Foo Yun Chee; editing by Grant McCool)
Source link : https://www.medscape.com/s/viewarticle/996510?src=rss
Author :
Publish date : 2023-09-18 17:08:48
Copyright for syndicated content belongs to the linked Source.
